Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ≥50% who progress on first-line immunotherapy: real-world data from a European cohort

BACKGROUND: In this real-world multicenter study we addressed the activity of post-progression anticancer treatments after first-line pembrolizumab in advanced non-small cell lung cancer (NSCLC) patients with PD-L1 ≥50%. METHODS: Clinico-pathological data of PD-L1 ≥50% advanced NSCLCs who failed fir...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Thorac Dis
Autors principals: Metro, Giulio, Addeo, Alfredo, Signorelli, Diego, Gili, Alessio, Economopoulou, Panagiota, Roila, Fausto, Banna, Giuseppe, De Toma, Alessandro, Rey Cobo, Juliana, Camerini, Andrea, Christopoulou, Athina, Lo Russo, Giuseppe, Banini, Marco, Galetta, Domenico, Jimenez, Beatriz, Collazo-Lorduy, Ana, Calles, Antonio, Baxevanos, Panagiotis, Linardou, Helena, Kosmidis, Paris, Garassino, Marina C., Mountzios, Giannis
Format: Artigo
Idioma:Inglês
Publicat: AME Publishing Company 2019
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6988053/
https://ncbi.nlm.nih.gov/pubmed/32030213
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jtd.2019.12.23
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars